Stock listing

NASDAQ:APRE Aprea Therapeutics, Inc. Stock

Home listing (NASDAQ) of Aprea Therapeutics, Inc.

Follow Aprea Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:APRE

$0.229 USD -0.264 (-53.5%)

Close on Nov 20, 2026

Past year -79.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.204 – $0.498 USDNov 20, 2026
Volume
2.44M sharesNov 20, 2026
Market cap
$3.25M USDAt the close on Nov 20, 2026 · price × 14.19M shares outstanding
52-week range
$0.204 – $1.490 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$259,714 USDMedian day 154,050 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Aprea Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:APRE · Home$0.229 USD-0.264 (-53.5%)2,440,300$0.498$0.498$0.204$0.493Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:APRE · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.229-0.264-53.5%$0.498$0.498$0.2042,440,300
$0.493+0.028+6.0%$0.461$0.500$0.451174,000
$0.465+0.012+2.6%$0.443$0.485$0.443128,300
$0.453+0.047+11.6%$0.395$0.486$0.390327,200
$0.406-0.010-2.4%$0.429$0.460$0.4001,646,400
$0.416-0.024-5.5%$0.473$0.473$0.41094,100
$0.440-0.005-1.1%$0.453$0.454$0.440149,400
$0.445-0.001-0.2%$0.440$0.467$0.43074,200
$0.446-0.055-11.0%$0.499$0.514$0.435158,700
$0.501-0.017-3.3%$0.513$0.534$0.50190,600
$0.518+0.023+4.6%$0.496$0.530$0.49565,600
$0.495-0.010-2.0%$0.505$0.505$0.471140,000
$0.505-0.010-1.9%$0.529$0.532$0.50520,800
$0.515+0.024+4.9%$0.488$0.517$0.48063,800
$0.491+0.006+1.2%$0.500$0.520$0.48689,100
$0.485-0.009-1.8%$0.479$0.521$0.460167,600
$0.494-0.044-8.2%$0.540$0.540$0.486171,000
$0.538+0.025+4.9%$0.512$0.540$0.512147,500
$0.513+0.064+14.3%$0.436$0.536$0.429187,900
$0.449-0.069-13.3%$0.520$0.520$0.410568,600
$0.518-0.024-4.4%$0.527$0.546$0.49589,200
$0.542-0.018-3.2%$0.559$0.559$0.511130,100
$0.560-0.001-0.2%$0.564$0.600$0.51181,600
$0.561+0.029+5.5%$0.545$0.567$0.511366,900
$0.532-0.052-8.9%$0.603$0.605$0.530201,100
$0.584-0.034-5.5%$0.658$0.658$0.573160,100
$0.618+0.035+6.0%$0.580$0.626$0.58065,400
$0.583-0.017-2.8%$0.611$0.611$0.58274,300
$0.600+0.007+1.2%$0.610$0.648$0.593136,900
$0.593-0.011-1.8%$0.610$0.615$0.581116,500
$0.604+0.046+8.2%$0.557$0.607$0.55770,400
$0.558-0.047-7.8%$0.605$0.610$0.550239,400
$0.605-0.031-4.9%$0.636$0.638$0.576249,900
$0.636-0.040-5.9%$0.680$0.680$0.634198,900
$0.676-0.019-2.7%$0.686$0.695$0.640296,500
$0.695-0.029-4.0%$0.716$0.736$0.685862,200
$0.724-0.026-3.5%$0.764$0.782$0.675779,600
$0.750-0.020-2.6%$0.780$0.820$0.741581,700
$0.770+0.018+2.4%$0.758$0.820$0.750591,600
$0.752-0.009-1.2%$0.760$0.771$0.74069,800
$0.761-0.019-2.4%$0.780$0.780$0.74153,300
$0.7800.0000.0%$0.800$0.800$0.76552,000
$0.780+0.048+6.6%$0.742$0.810$0.742282,000
$0.732-0.005-0.7%$0.760$0.760$0.700189,600
$0.737-0.023-3.0%$0.760$0.760$0.73096,700
$0.760+0.010+1.3%$0.780$0.780$0.74080,000
$0.750+0.019+2.6%$0.750$0.772$0.730117,200
$0.731-0.018-2.4%$0.729$0.757$0.711186,000
$0.749-0.032-4.1%$0.820$0.820$0.733184,200
$0.781+0.007+0.9%$0.771$0.843$0.760120,300
$0.774-0.015-1.9%$0.796$0.820$0.765127,300
$0.789-0.002-0.3%$0.781$0.810$0.78161,300
$0.791-0.044-5.3%$0.850$0.871$0.783134,700
$0.835+0.041+5.2%$0.840$0.880$0.779317,800
$0.794-0.012-1.5%$0.800$0.809$0.79189,400
$0.806-0.014-1.7%$0.820$0.820$0.780111,700
$0.820-0.016-1.9%$0.810$0.854$0.799168,800
$0.836+0.036+4.5%$0.780$0.900$0.780462,400
$0.800-0.039-4.6%$0.845$0.852$0.780476,000
$0.839-0.021-2.4%$0.880$0.910$0.820344,000
$0.860-0.120-12.2%$0.990$0.990$0.8101,182,000
$0.980+0.030+3.2%$1.090$1.160$0.9232,818,700
$0.950+0.145+18.0%$0.815$0.990$0.8022,148,900
$0.805+0.165+25.8%$0.704$0.850$0.6802,803,200
$0.6400.0000.0%$0.657$0.670$0.62314,600
$0.640-0.031-4.6%$0.672$0.693$0.63338,900

Splits

1 split · NASDAQ:APRE · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
NASDAQ:APRE
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Aprea Therapeutics, Inc. news

Aprea Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 99 in all · newest Nov 20, 2026 · oldest 2019
Decks
38 decks · latest Nov 20, 2026

Where Aprea Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:APRE · Home listing · This pageNASDAQUnited StatesUSD
BOATS:APREBOATSUnited StatesUSD

Valuation

Price/book 0.1× against a median of 0.7×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$34.60M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.73

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Aprea Therapeutics, Inc. · NASDAQ:APREUS$3.25M−US$34.60Mn/an/an/a0.1×n/a0.0×0.73
Liminatus Pharma, Inc. · NASDAQ:LIMNUS$3.37MUS$1.80Mn/an/an/a11.2×n/a4.8×0.94
Xenetic Biosciences, Inc. · NASDAQ:XBIOUS$3.28M−US$2.53Mn/a−0.8×n/a0.7×−123.7%0.0×1.46
Spago Nanomedical AB · OMXSTO:SPAGOUS$3.20MUS$22,063n/a5.6×n/a1.0×n/a0.0×n/a
Kiora Pharmaceuticals, Inc. · NASDAQ:KPRXUS$3.19M−US$12.81Mn/a−12.8×n/a0.2×n/a0.0×1.54
Azitra Inc · AMEX:AZTRUS$3.13M−US$618,677n/an/an/a0.7×n/a0.0×0.60
NuCana plc · NASDAQ:NCNAUS$3.12M−US$21.38Mn/an/an/a0.1×n/a0.0×1.58
Revive Therapeutics Ltd. · CSE:RVVUS$3.10MUS$3.14Mn/an/an/an/an/an/a0.56
Skye Bioscience, Inc. · NASDAQ:SKYEUS$3.10M−US$1.71Mn/an/an/a2.3×n/a0.0×0.85
Creative Medical Technology Holdings, Inc. · NASDAQ:CELZUS$3.06M−US$3.79Mn/a−1,263×n/a0.4×n/a0.0×1.53
Oncology Pharma Inc. · OTC:ONPHUS$3.04Mn/an/an/an/an/an/an/a1.62
Median of the othersUS$3.13M−US$1.71M−6.8×0.7×−123.7%0.0×1.46

Forecasts

3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
3.30 USD · Analysts' mean
EPS, year to Dec 2026
-0.39 · 3 analysts

Team and board

Officers

OfficerRole
Oren GiladPresident and Chief Executive Officer
John P. HamillSenior Vice President and Chief Financial Officer
Brian WileySenior Vice President of Corporate Development & Strategy
Eugene KennedyChief Medical Advisor
Ze’ev WeissChief Business Advisor

Board

DirectorRole
Bernd R. SeizingerDirector
Gabriela GruiaDirector
Jean-Pierre BizzariDirector
John B. HennemanDirector
Marc DueyDirector
Michael GrissingerDirector
Rifat PamukcuDirector

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · Before open−1.9%
Q2 2026Aug 12, 2026 · Before open+3.5%
Q1 2026May 13, 2026+4.6%
Q4 2025Mar 16, 2026 · Before open+2.7%
Q3 2025Nov 12, 2025 · Before open−4.5%
Q2 2025Aug 12, 2025 · Before open+0.6%
Q1 2025May 12, 2025 · Before open−4.3%
Q4 2024Mar 25, 2025 · Before open−3.1%
Q3 2024Nov 7, 2024 · Before open−2.6%
Q2 2024Aug 12, 2024 · Before open−4.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open+5.4%
Q4 2023Mar 26, 2024 · Before open−2.7%
Q3 2023Nov 9, 2023 · After close−5.2%
Q2 2023Aug 10, 2023 · Before open+2.6%
Q1 2023May 15, 2023 · After close+6.2%
Q4 2022Mar 30, 2023 · After close−3.5%
Q3 2022Nov 9, 2022 · After close−10.9%
Q2 2022Aug 11, 2022 · After close−3.9%
Q1 2022May 16, 2022 · Before open−19.1%
Q4 2021Mar 15, 2022 · After close+14.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck31 slidesNov 20, 2026
Investor Presentation (November 2026)Investor deck29 slidesNov 4, 2026
Investor Presentation (August 2026)Investor deck26 slidesAugust 2026
Investor Presentation (May 2026)Investor deck26 slidesMay 13, 2026
Investor Presentation (March 2026)Investor deck28 slidesMar 30, 2026
Investor Presentation (March 2026)Investor deck27 slidesMar 16, 2026
Investor Presentation (January 2026)Investor deck29 slidesJan 29, 2026
Investor Presentation (January 2026)Investor deck23 slidesJan 9, 2026
Investor Presentation (November 2025)Investor deck20 slidesNov 12, 2025
Investor Presentation (October 2025)Investor deck21 slidesOct 15, 2025
All 38 decks
DeckKindSlidesDate
Investor Presentation (September 2025)Investor deck21 slidesSep 8, 2025
Corporate Update (August 2025)Corporate update36 slidesAug 12, 2025
Investor Presentation (May 2025)Investor deck32 slidesMay 14, 2025
Investor Presentation (March 2025)Investor deck34 slidesMar 25, 2025
Investor Presentation (January 2025)Investor deck37 slidesJan 13, 2025
Investor Presentation (November 2024)Investor deck37 slidesNov 7, 2024
Corporate Update (August 2024)Corporate update35 slidesAug 12, 2024
Technical Presentation (June 2024)Technical25 slidesJun 24, 2024
Investor Presentation (June 2024)Investor deck35 slidesJun 17, 2024
Corporate Update (May 2024)Corporate update35 slidesMay 14, 2024
Investor Presentation (April 2024)Investor deck39 slidesApr 10, 2024
Corporate Update (March 2024)Corporate update35 slidesMar 26, 2024
Investor Presentation (February 2024)Investor deck34 slidesFeb 6, 2024
Investor Presentation (January 2024)Investor deck34 slidesJan 4, 2024
Corporate Update (November 2023)Corporate update34 slidesNov 9, 2023
Investor Presentation (October 2023)Investor deck34 slidesOct 13, 2023
Investor Presentation (September 2023)Investor deck27 slidesSep 11, 2023
Investor Presentation (August 2023)Investor deck25 slidesAug 10, 2023
Investor Presentation (May 2023)Investor deck25 slidesMay 15, 2023
Investor Presentation (March 2023)Investor deck25 slidesMar 30, 2023
Investor Presentation (February 2023)Investor deck24 slidesFeb 10, 2023
DDR Inhibitors Summit 2023Conference15 slidesJan 26, 2023
DDR Inhibitors Summit 2023Conference17 slidesJan 26, 2023
Investor Presentation (January 2023)Investor deck24 slidesJan 9, 2023
Investor Presentation (May 2022)Investor deck29 slidesMay 17, 2022
J.P. Morgan 40th Annual Healthcare Conference January 2022Conference23 slidesJan 13, 2022
J.P. Morgan 39th Annual Healthcare Conference 2021Conference20 slidesJan 12, 2021
J.P. Morgan 38th Annual Healthcare Conference 2020Conference20 slidesJan 13, 2020

Open Decks

Financings

RaiseDate
Private placement of shares of common stock (or pre-funded warrants) with warrants
Announced: about US$5.6M · US$0.89 a share · Warrants at US$0.765 · Maxim Group LLC
Dealers: Maxim Group LLC (lead)
Insiders: Certain insiders of the Company are among the purchasers
Use of proceeds: General corporate purposes and research and development expenses
Jan 29, 2026
Private placement of private placement financing
Closed: US$3.1M raised · US$1.165 a share · Warrants at US$1.04 for 60 months · Maxim Group LLC
Dealers: Maxim Group LLC (lead)
Insiders: The CEO, the CFO and a Board member participated alongside external investors
Use of proceeds: General corporate purposes and research and development expenses
Dec 18, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$15.00 a share on Oct 2, 2019.

Price
US$15.00 a share
Shares offered
5,666,667 shares of common stock
Offering size
US$85 million
Underwriters' option
Up to 850,000 more shares
Listing
APRE on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, Morgan Stanley, RBC Capital Markets · In the order on the cover
Shares delivered
On or about Oct 7, 2019

Steps

StepWhen
Draft sent to the SEC in confidenceJul 12, 2019
Filed publiclySep 6, 2019
Amended 4 timesNewest Oct 2, 2019
Shares registered with an exchangeSep 30, 2019
Declared effective by the SECOct 2, 2019
Final prospectus, with the priceOct 4, 2019

Open IPO · From the cover of the final prospectus (424B4) filed Oct 4, 2019

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2013
Revenue285.8K1.50M583.2K0000000
Cost of revenue21.7K9.36M7.05K16.4M271.7K229.6K170.3K8.32K7.93K0
Gross profit264.0K-7.86M576.2K-16.4M-271.7K-229.6K-170.3K-8.32K-7.93K0
Research and development7.04M9.36M7.63M16.4M23.9M37.9M21.0M14.2M13.4M
Selling, general and administrative6.48M6.46M8.43M21.0M13.6M14.9M8.59M2.29M2.46M246.5K
Operating income-13.2M-14.3M-15.5M-113.4M-37.4M-52.8M-29.5M-16.5M-15.9M-246.5K
Depreciation and amortization21.7K22.3K7.05K4.40K12.8K28.8K11.1K8.32K7.93K
EBITDA-13.2M-14.3M-15.5M-113.4M-37.4M-52.8M-29.5M-16.5M-15.8M
Interest expense448.7K1.65K222.7K156.4K182150
Income before tax-12.6M-13.0M-14.3M-112.7M-37.1M-53.5M-28.1M-15.5M-15.2M-436.2K
Income tax0000000000
Net income-12.6M-13.0M-14.3M-112.7M-37.1M-53.5M-28.1M-15.5M-15.2M-436.2K
Earnings per share, basic-1.93-2.35-3.95-67.99-34.88-50.61-4.67-13.45-13.17
Earnings per share, diluted-1.93-2.35-3.95-67.99-34.88-50.61-4.67-13.45-13.17

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2013
Cash and equivalents14.6M22.8M21.6M28.8M53.1M89.0M130.1M65.7M24.4M
Short-term investments00
Inventory00
Current assets15.6M23.6M22.5M30.2M56.6M92.4M133.0M66.0M24.7M
Property, plant and equipment59.8K81.5K88.4K2.32K23.9K38.5K41.6K24.4K30.3K
Goodwill00
Total assets15.9M24.0M22.7M30.2M56.8M92.8M133.6M66.0M24.8M
Accounts payable713.7K1.35M1.67M842.8K1.77M4.50M2.18M1.74M1.66M4.22M
Current liabilities2.76M3.36M4.39M3.20M7.32M15.3M9.06M4.87M4.30M5.70M
Long-term debt00
Total debt190.5K335.2K545.0K
Total liabilities3.49M4.67M4.39M3.20M7.32M15.4M9.36M4.87M60.5M5.70M
Shareholders' equity12.4M19.3M17.0M25.6M49.5M77.4M124.2M-51.4M-35.8M
Shares outstanding8.19M5.48M3.74M2.66M1.09M21.2M21.0M1.16M21.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2013
Cash from operations-12.9M-13.6M-12.2M-25.0M-37.7M-41.8M-26.7M-15.3M-14.0M
Capital spending0-15.5K-93.1K00-25.7K-30.9K-3.70K-3.70K0
Free cash flow-12.9M-13.6M-12.3M-25.0M-37.7M-41.8M-26.7M-15.3M-14.0M
Cash from investing-15.5K-93.1K-25.7K-30.9K-3.70K-3.70K
Cash from financing4.64M14.8M5.14M683.0K1.75M150.9K92.6M56.4M23.3M
Dividends paid00
Share buybacks92.6M56.4M23.3M
Change in cash-8.25M1.25M-7.13M-24.3M-35.9M-41.7M65.8M41.1M9.34M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Current reportSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
8-K · Current reportAug 28, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
8-K · Current reportJul 23, 2026Current reportSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
8-K · Current reportJun 17, 2026Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
424B7 · ProspectusMay 15, 2026Offer documentSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 30, 2026Other filingsSEC
424B3 · ProspectusApr 29, 2026Offer documentSEC
CORRESP · Letter to the SECApr 27, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 27, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 27, 2026Big-stake noticeSEC
S-3 · Registration statementApr 22, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementApr 20, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeApr 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 1, 2026Big-stake noticeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
8-K · Current reportApr 1, 2026Current reportSEC
8-K · Current reportMar 30, 2026Material contractSEC
EFFECT · Notice that a registration is effectiveMar 20, 2026Other filingsSEC
424B3 · ProspectusMar 19, 2026Offer documentSEC
CORRESP · Letter to the SECMar 17, 2026Other filingsSEC
S-3/A · Registration statement, amendedMar 17, 2026Offer documentSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 16, 2026Offer documentSEC
CORRESP · Letter to the SECMar 16, 2026Other filingsSEC
10-K · Annual reportMar 16, 2026Annual reportSEC
8-K · Current reportMar 16, 2026ResultsSEC
UPLOAD · Letter from the SECFeb 24, 2026Other filingsSEC
S-3 · Registration statementFeb 20, 2026Offer documentSEC
8-K · Current reportFeb 18, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
8-K · Current reportJan 29, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 28, 2026Big-stake noticeSEC
8-K · Current reportJan 23, 2026Current reportSEC
8-K · Current reportJan 9, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveDec 30, 2025Other filingsSEC
424B3 · ProspectusDec 29, 2025Offer documentSEC
DDec 23, 2025Other filingsSEC
CORRESP · Letter to the SECDec 23, 2025Other filingsSEC
UPLOAD · Letter from the SECDec 23, 2025Other filingsSEC
S-3 · Registration statementDec 19, 2025Offer documentSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
8-K · Current reportDec 9, 2025Material contractSEC
S-8 · Registration statement for employee plansDec 8, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeNov 17, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
8-K · Current reportOct 24, 2025Current reportSEC
8-K · Current reportOct 15, 2025Current reportSEC
8-K · Current reportSep 8, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
8-K · Current reportJun 9, 2025Meeting outcomeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
ARS · Annual report to shareholdersApr 22, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 22, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 8, 2025Big-stake noticeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
10-K · Annual reportMar 25, 2025Annual reportSEC
8-K · Current reportMar 25, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2025Big-stake noticeSEC
8-K · Current reportFeb 5, 2025Current reportSEC
8-K · Current reportJan 13, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
8-K · Current reportNov 8, 2024Material contractSEC
424B5 · ProspectusNov 8, 2024Offer documentSEC
8-K · Current reportNov 7, 2024ResultsSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
4 · Change in ownershipOct 25, 2024Insider tradeSEC
4 · Change in ownershipOct 24, 2024Insider tradeSEC
8-K · Current reportOct 23, 2024Current reportSEC
4 · Change in ownershipOct 17, 2024Insider tradeSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
SC 13G · Big-stake noticeOct 10, 2024Big-stake noticeSEC
8-K · Current reportOct 9, 2024ResultsSEC
S-8 · Registration statement for employee plansAug 21, 2024Offer documentSEC
8-K · Current reportAug 12, 2024ResultsSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
8-K · Current reportJun 20, 2024Meeting outcomeSEC
8-K · Current reportJun 17, 2024Current reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
4 · Change in ownershipMay 2, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 2, 2024Insider tradeSEC
424B3 · ProspectusApr 30, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 30, 2024Other filingsSEC
CORRESP · Letter to the SECApr 25, 2024Other filingsSEC
ARS · Annual report to shareholdersApr 25, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2024Meeting noticeSEC
8-K · Current reportApr 10, 2024Current reportSEC
UPLOAD · Letter from the SECApr 8, 2024Other filingsSEC
S-3 · Registration statementApr 3, 2024Offer documentSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
8-K · Current reportMar 26, 2024ResultsSEC
10-K · Annual reportMar 26, 2024Annual reportSEC
4 · Change in ownershipMar 14, 2024Insider tradeSEC
4 · Change in ownershipMar 14, 2024Insider tradeSEC
4 · Change in ownershipMar 14, 2024Insider tradeSEC
4 · Change in ownershipMar 14, 2024Insider tradeSEC
8-K · Current reportMar 12, 2024Material contractSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
424B3 · ProspectusFeb 8, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
8-K · Current reportFeb 6, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveFeb 5, 2024Other filingsSEC
424B3 · ProspectusFeb 2, 2024Offer documentSEC
8-K · Current reportFeb 2, 2024ResultsSEC
CORRESP · Letter to the SECJan 31, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 30, 2024Other filingsSEC
8-K · Current reportJan 26, 2024Material contractSEC
S-3 · Registration statementJan 26, 2024Offer documentSEC
8-K · Current reportJan 4, 2024Current reportSEC
S-8 · Registration statement for employee plansNov 9, 2023Offer documentSEC
8-K · Current reportNov 9, 2023ResultsSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportOct 16, 2023Current reportSEC
8-K · Current reportOct 13, 2023Current reportSEC
8-K · Current reportSep 11, 2023Current reportSEC
4 · Change in ownershipAug 24, 2023Insider tradeSEC
4 · Change in ownershipAug 24, 2023Insider tradeSEC
4 · Change in ownershipAug 24, 2023Insider tradeSEC
4 · Change in ownershipAug 24, 2023Insider tradeSEC
4 · Change in ownershipAug 24, 2023Insider tradeSEC
4 · Change in ownershipAug 24, 2023Insider tradeSEC
4 · Change in ownershipAug 24, 2023Insider tradeSEC
3 · Initial statement of ownershipAug 24, 2023Insider tradeSEC
8-K · Current reportAug 24, 2023Management or board changeSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
8-K · Current reportAug 10, 2023ResultsSEC
ARS · Annual report to shareholdersJul 11, 2023Annual reportSEC
DEF 14A · Proxy statementJul 11, 2023Meeting noticeSEC
8-K · Current reportJul 5, 2023Current reportSEC
4 · Change in ownershipJun 8, 2023Insider tradeSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
8-K · Current reportMay 15, 2023ResultsSEC
4 · Change in ownershipMay 8, 2023Insider tradeSEC
3 · Initial statement of ownershipMay 8, 2023Insider tradeSEC
8-K · Current reportMay 8, 2023Management or board changeSEC
10-K/A · Annual report, amendedApr 28, 2023Annual reportSEC
8-K · Current reportApr 18, 2023Current reportSEC
10-K · Annual reportMar 30, 2023Annual reportSEC
8-K · Current reportMar 30, 2023ResultsSEC
4 · Change in ownershipMar 13, 2023Insider tradeSEC
8-K · Current reportMar 13, 2023Current reportSEC
SC 13G · Big-stake noticeMar 3, 2023Big-stake noticeSEC
8-K · Current reportMar 1, 2023Current reportSEC

This page holds 200 of 447 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Aprea Therapeutics, Inc.’s releases · as of Aug 12, 2026

Common shares
14,191,136
Fully diluted
14,191,136

Fully diluted

LineSharesAs of
Common shares14,191,136Aug 12, 2026

Warrants and options

Lot
Warrants · US$1.04 · expire about Dec 2030

Share count over time

CountShares
Nov 22, 202614,191,136
Aug 12, 20268,192,538

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
AIGH Capital Management LLC1.02M7.2%US$762KNo changeNov 2, 2026
Soleus Capital Management, L.P.1M7.0%US$750KNewNov 16, 2026
Vestal Point Capital, LP350K2.5%US$263KNo changeNov 16, 2026
Sphera Funds Management LTD.270K1.9%US$203KNo changeNov 16, 2026
Nantahala Capital Management, LLC206K1.4%US$154K−206KNov 13, 2026
Renaissance Technologies99,6000.70%US$74,700−6,200Nov 12, 2026
Vanguard87,6760.62%US$65,757+26,330Nov 13, 2026
Geode Capital74,5490.53%US$55,916−320Nov 6, 2026
BNP Paribas46,2110.33%US$34,658+1,000Nov 12, 2026
Virtu Financial LLC43,0830.30%US$32,000NewNov 17, 2026
All 27 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Diadema Partners LP28,8720.20%US$21,654−16,035Nov 16, 2026
Morgan Stanley26,5300.19%US$19,898+700Nov 13, 2026
Hrt Financial LP26,4650.19%US$19,000NewNov 13, 2026
LPL Financial LLC19,0520.13%US$14,289+3,000Nov 6, 2026
Jane Street13,8820.10%US$10,412NewNov 12, 2026
Northern Trust13,7050.10%US$10,279No changeNov 16, 2026
XTX Topco Ltd11,6780.08%US$8,759+1,113Nov 16, 2026
BlackRock7,1730.05%US$5,380No changeNov 13, 2026
Tower Research Capital LLC (TRC)3,7120.03%US$2,784+122Nov 16, 2026
Pinnacle Financial Group, Inc.2,0000.01%US$1,500First reportNov 16, 2026
Group One Trading LLC577<0.01%US$433No changeNov 10, 2026
Osaic Holdings, Inc.295<0.01%US$221No changeNov 12, 2026
WealthCollab, LLC158<0.01%US$119No changeNov 12, 2026
UBS150<0.01%US$113+147Nov 10, 2026
TD40<0.01%US$29NewOct 16, 2026
SBI Securities Co., Ltd.16<0.01%US$12No changeOct 21, 2026
Barclays2<0.01%US$2−471Nov 6, 2026

Funds

HolderSharesOf the companyValueChangeAs of
Fidelity Extended Market Index Fund80,9250.57%US$72,234+9,800May 31, 2026
Vanguard Extended Market Index Fund19,6220.14%US$15,743No changeJun 30, 2026
Fidelity Total Market Index Fund7,1970.05%US$6,424No changeMay 31, 2026
Fidelity Series Total Market Index Fund5,8510.04%US$5,223No changeMay 31, 2026
Fidelity Nasdaq Composite Index Fund2,1000.01%US$1,874No changeMay 31, 2026
Diversified Equity Alpha Master Portfolio289<0.01%US$232No changeJun 30, 2026

Big stakes

HolderStakeSharesDate
Vestal Point Capital, LP9.90%22.7MMar 31, 2026
LYTTON LAURENCE W3.20%391KJun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
John B Henneman III
Other companies: Orthofix Medical Inc. (Director · Since at least Jan 5, 2023); Anika Therapeutics Inc. (Director · Since at least Sep 3, 2020); R1 RCM Inc (Director · Apr 3, 2017 – Nov 19, 2024 · Past); Accretive Health Inc (Director · Feb 16, 2016 – Jan 3, 2017 · Past); SeaSpine Holdings Corp (Director · Jul 1, 2015 – Jan 5, 2023 · Past); Lumos Pharma Inc (Chief Administrative Officer · Oct 1, 2014 – Oct 1, 2018 · Past); Integra LifeSciences Holdings Corporation (CorpVP, CAO · Jan 6, 2006 – Aug 25, 2014 · Past)
Director · Since at least Oct 2, 2019
Michael A. Kelly
Other companies: Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Amicus Therapeutics Inc (Director · Since at least Dec 1, 2020); DMC Global Inc. (Director · Since at least Jul 24, 2020); NeoGenomics, Inc. (Board Member · Since at least Jul 15, 2020); Hookipa Pharma Inc (Director · Apr 17, 2019 – Jun 30, 2022 · Past)
Director · Sep 28, 2020 – Jun 30, 2021 · Past
Scott M Rocklage
Other companies: Pulmatrix, Inc. (Director · Jun 15, 2015 – Feb 3, 2016 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Jun 13, 2018 · Past); EPIRUS Biopharmaceuticals Inc (Director · Jul 15, 2014 – Jun 5, 2015 · Past); Achaogen Inc (Director · Mar 11, 2014 – Mar 11, 2014 · Past); Relypsa Inc (Director · Nov 14, 2013 – Nov 20, 2013 · Past)
Director · Oct 2, 2019 – Jun 30, 2020 · Past
Christian S. Schade
Other companies: Integra LifeSciences Holdings Corporation (Director · Since at least May 17, 2006); Omega Therapeutics Inc (Director · Jul 10, 2023 – Jun 20, 2024 · Past); Omthera Pharmaceuticals Inc (Executive VP and CFO · Apr 11, 2013 – Jul 16, 2013 · Past); NRG Energy, Inc. (Exec VP & Chief Financial Ofc · Mar 29, 2010 – Mar 29, 2011 · Past)
Director · Oct 2, 2019 – Jul 28, 2022 · Past
Jean-Pierre Bizzari
Other companies: ADC Therapeutics SA (Non-Executive Director · Since at least Jan 2, 2024); Palvella Therapeutics, Inc. (Director · Jun 29, 2015 – Jan 25, 2020 · Past); Celator Pharmaceuticals Inc (Director · Feb 27, 2015 – Jul 12, 2016 · Past); Halozyme Therapeutics, Inc. (Director · Jan 17, 2015 – May 5, 2023 · Past)
Director · Since at least Aug 23, 2023
John P. Hamill
Other companies: Windtree Therapeutics, Inc. (SVP & CFO · Jul 20, 2020 – Jul 26, 2022 · Past); Trevena, Inc. (VP Fin,Princ Fin&Acct Officer · Jun 11, 2018 – May 31, 2019 · Past); Cellectar Biosciences, Inc. (Interim CFO · Sep 5, 2017 – Sep 5, 2017 · Past)
Senior Vice President and Chief Financial Officer · Since at least Jan 30, 2023
Michael Grissinger
Other companies: Lipocine Inc. (Director · Since at least Aug 3, 2026); Adicet Bio, Inc. (Director · Since at least Nov 5, 2018); Akari Therapeutics PLC (Director · Jan 1, 2024 – Jun 28, 2024 · Past)
Director · Since at least May 16, 2022
Bernd R. Seizinger
Other companies: Oncolytics Biotech Inc. (Director · Since at least Jan 1, 2026); Aptose Biosciences Inc (Director · Sep 13, 2022 – Feb 5, 2024 · Past)
Director · Since at least Oct 2, 2019
Eugene Kennedy
Other companies: Galera Therapeutics, Inc. (Chief Medical Officer · Sep 1, 2022 – Feb 25, 2023 · Past); Lumos Pharma Inc (Chief Medical Officer · Nov 13, 2017 – Feb 1, 2021 · Past)
Chief Medical Advisor · Since at least Oct 16, 2026
Fouad Namouni
Other companies: Vor Biopharma Inc. (Chair of the Nominating and Corporate Governance Committee · Since at least Apr 30, 2024); Blueprint Medicines Corp (PRESIDENT, R & D · Since at least Sep 1, 2020)
Director · Jun 26, 2020 – Jun 30, 2021 · Past
All 27 people
PersonSeat
Gabriela Gruia
Other companies: TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); Molecular Templates Inc (Director · Mar 1, 2022 – Sep 27, 2024 · Past)
Director · Since at least May 5, 2023
Richard Peters
Other companies: Kineta Inc. (Director · Since at least Dec 22, 2020); Merrimack Pharmaceuticals Inc (President and CEO, Director · Feb 6, 2017 – May 8, 2019 · Past)
Director · Since at least Jun 26, 2020
Brian Wiley
Other companies: Lumos Pharma Inc (Chief Commercial Officer · Jan 2, 2013 – Mar 9, 2018 · Past)
Senior Vice President of Corporate Development & Strategy · Since at least Nov 4, 2026
Eyal C Attar
Other companies: Vor Biopharma Inc. (CHIEF MEDICAL OFFICER · Oct 11, 2022 – Feb 13, 2025 · Past)
SVP, Chief Medical Officer, Director · Oct 2, 2019 – Jun 3, 2022 · Past
Guido Magni
Other companies: Adolor Corp (Director · Jun 6, 2008 – Dec 7, 2011 · Past)
Director · Oct 2, 2019 – Oct 7, 2019 · Past
Johan Christenson
Other companies: Fusion Pharmaceuticals Inc (Director · Jun 25, 2020 – Jun 30, 2020 · Past)
Director · Oct 2, 2019 – Jun 30, 2020 · Past
Scott Coiante
Other companies: Lexicon Pharmaceuticals, Inc. (Senior Vice President and Chief Financial Officer · Since at least Jan 2, 2025)
SVP, Chief Financial Officer · Oct 2, 2019 – Jul 28, 2022 · Past
Gregory Alan KorbelSVP, Chief Operating Officer · Oct 2, 2019 – Jul 28, 2022 · Past
Gregory S WesselsSVP, Chief Commercial Officer · Sep 16, 2020 – Feb 25, 2021 · Past
John B. HennemanDirector · Since at least Jun 17, 2026
Jonathan HeppleDirector · Oct 2, 2019 – Jun 30, 2020 · Past
Lars B AbrahmsenSVP, Chief Scientific Officer · Oct 2, 2019 – Mar 10, 2022 · Past
Marc DueyDirector · Since at least May 16, 2022
Nadeem Q MirzaChief Medical Officer · May 1, 2024 – May 1, 2024 · Past
Oren GiladPresident/CEO, Director · Since at least May 16, 2022
Rifat PamukcuDirector · Since at least May 16, 2022
Ze’ev WeissChief Business Advisor · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Aprea Therapeutics, Inc.